Price Chart

Executive Summary

Nurix Therapeutics entered into a global license and collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, a potential best-in-class BTK degrader, across oncology, immunology, and neurology. Roche will make an upfront cash payment of $700 million, with total potential payments up to $2.3 billion including milestones, and development costs will be split 40/60 (Nurix/Roche) with a 50/50 U.S. profit share and tiered ex-U.S. royalties. This deal provides significant non-dilutive capital, validates the asset's potential, and accelerates Nurix's path to becoming a fully integrated biopharma, making this a transformative event for the company.

Key Financial Metrics

Key Facts

• Roche to pay $700 million upfront cash to Nurix for exclusive worldwide license to bexobrutideg (NX-5948), an oral BTK degrader.
• Total potential payments to Nurix of up to $2.3 billion including development, regulatory, and sales milestones.
• Nurix and Roche will co-develop and co-commercialize in the U.S. with a 50/50 profit/loss split; Roche leads ex-U.S. commercialization with tiered royalties (low-to-high teens).
• Global development costs shared 40% by Nurix and 60% by Roche.
• Clinical development plan includes Phase 2/3 trials in CLL and expansion into multiple sclerosis (MS) and chronic spontaneous urticaria (CSU) with planned Phase 2 trials.
• Nurix reported a pro-forma cash balance of ~$1.24 billion after the upfront payment, extending its cash runway significantly.
• Collaboration covers malignant hematology, immunology, and neurology targeting a combined addressable market of ~$48 billion projected for 2030.
• Nurix retains 50/50 U.S. profit share and co-promotion rights, accelerating its evolution into a fully integrated biopharmaceutical company.
• Deal is subject to HSR Act waiting period expiration and other antitrust clearance.
• Goldman Sachs acted as exclusive financial advisor to Nurix.

Financial Impact

Nurix receives $700 million upfront in cash, with potential total milestone payments of up to $2.3 billion. Pro-forma cash balance climbs to approximately $1.24 billion, eliminating near-term funding risk and funding 40% of global development costs.

Risk Factors

• Deal completion is contingent on HSR Antitrust Act waiting period expiration; delays or conditions could impact timing.
• Clinical and regulatory risks remain; bexobrutideg is still investigational and may face safety/efficacy hurdles.
• Nurix bears 40% of development costs, which could pressure cash if trials are more expensive than anticipated or if milestones are delayed.
• Co-commercialization complexity in the U.S. could create operational challenges and misaligned incentives.
• Competition from existing BTK inhibitors and other degraders could limit market share.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status

Related Tickers